KeyBank National Association
COGT icon

KeyBank National Association’s Cogent Biosciences COGT Stock Holding History

KeyBank National Association’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,400
Closed -$195K – 1058
2018
Q2 		$195K Buy
+3,400
New +$163K ﹤0.01% 993

Other funds holding COGT

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KeyBank National Association's COGT Position: Q3 2018 in Review

KeyBank National Association sold out of Cogent Biosciences (COGT) in Q3 2018, closing a stake of 3,400 shares — an estimated $195K sold.

KeyBank National Association first reported a position in COGT in Q2 2018 and held it in 1 quarter. The position peaked at $195K in Q2 2018. 48 funds tracked by Wall St. Rank hold COGT as of Q3 2018.

  • KeyBank National Association reported no remaining Cogent Biosciences position as of Q3 2018 after selling out during the quarter.
  • KeyBank National Association sold 3,400 Cogent Biosciences shares in Q3 2018, an estimated $195K.
  • KeyBank National Association first reported a position in Cogent Biosciences in Q2 2018 and held it in 1 quarter.
  • KeyBank National Association's Cogent Biosciences position peaked at $195K in Q2 2018.
  • 48 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2018.

Based on KeyBank National Association's 13F filing for Q3 2018, filed 8 Nov 2018.